The availability of child-friendly cancer treatments remains a critical gap in global health. To address this, WHO has launched a public consultation on the Target Product Profile (TPP) for Paediatric Formulations of key oncology medicines, including cyclophosphamide, etoposide, mercaptopurine, methotrexate, procarbazine, and temozolomide.

Many essential cancer treatments were designed for adults, leaving children without optimal formulations. By defining clear product expectations, this TPP aims to guide the development of better, age-appropriate medicines that improve safety, efficacy, and access for paediatric patients.

WHO is calling on healthcare professionals, researchers, industry experts, and advocates to provide input and ensure these medicines meet the needs of children worldwide. Deadline for feedback: 31 March, 2025 at 23:59 CET

Join the consultation and share your insights https://lnkd.in/dBuNv2vf